alexa Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker.


Journal of Integrative Oncology

Author(s): Ljungberg B, Rasmuson T, Grankvist K, Ljungberg B, Rasmuson T, Grankvist K, Ljungberg B, Rasmuson T, Grankvist K, Ljungberg B, Rasmuson T, Grankvist K

Abstract Share this page

Abstract Erythropoietin levels in serum were analyzed in 165 patients with renal cell carcinoma. All samples were taken before therapy and stored at -80 degrees C. Erythropoietin, a glucoprotein produced by the renal cortex was quantified by an enzyme immunoassay. Fifty-five of 165 patients (33\%) had elevated serum levels. In patients with metastatic disease (M+), elevated levels were found in 24 of 65 cases (38\%). Patients with high-grade tumors had significantly more often increased erythropoietin than those with low-grade tumors. No correlation between erythrocytosis and elevation of erythropoietin in serum was found. There was a significant difference in survival between patients with normal and patients with elevated erythropoietin levels (p = 0.013). The study shows that erythropoietin is a tumor marker with a low sensitivity. However, it correlates with stage and grade and provides prognostic information.
This article was published in Eur Urol and referenced in Journal of Integrative Oncology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version